<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Regulatory T cells (Treg) expressing the transcription factor forkhead-box protein P3 (Foxp3) have been identified to counteract anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> immune responses during <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Besides, Foxp3 presentation by <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells itself may also allow them to evade from effector T-cell responses, resulting in a survival benefit of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>For <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) the clinical relevance of Foxp3 has not been evaluated in detail </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore the aim of this study was to study its impact in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS AND FINDINGS: Gene and protein analysis of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues from patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> was performed to quantify the expression of Foxp3 in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> infiltrating Treg and <z:hpo ids='HP_0003003'>colon cancer</z:hpo> cells </plain></SENT>
<SENT sid="5" pm="."><plain>The results were correlated with clinicopathological parameters and patients overall survival </plain></SENT>
<SENT sid="6" pm="."><plain>Serial morphological analysis demonstrated Foxp3 to be expressed in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="7" pm="."><plain>High Foxp3 expression of the <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells was associated with poor prognosis compared to patients with low Foxp3 expression </plain></SENT>
<SENT sid="8" pm="."><plain>In contrast, low and high Foxp3 level in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> infiltrating Treg cells demonstrated no significant differences in overall patient survival </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: Our findings strongly suggest that Foxp3 expression mediated by <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells rather than by Treg cells contribute to disease progression </plain></SENT>
</text></document>